Provided by Tiger Fintech (Singapore) Pte. Ltd.

Editas Medicine

2.05
+0.290016.48%
Pre-market: 1.91-0.1400-6.83%04:36 EST
Volume:9.16M
Turnover:18.98M
Market Cap:169.22M
PE:-0.80
High:2.25
Open:1.85
Low:1.82
Close:1.76
Loading ...

Editas Medicine Inc - Has Operational Runway Into Q2 2027

THOMSON REUTERS
·
13 Jan

Editas Medicine Inc - to Submit at Least One Ind/Cta by 2027

THOMSON REUTERS
·
13 Jan

Editas Medicine Highlights New in Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-Year Strategic Priorities

THOMSON REUTERS
·
13 Jan

Press Release: Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities

Dow Jones
·
13 Jan

Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?

Zacks
·
08 Jan

Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire
·
06 Jan

Why Is Editas Medicine, Inc. (EDIT) Among the Top CRISPR Stocks to Invest In?

Insider Monkey
·
31 Dec 2024

EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce

Zacks
·
16 Dec 2024

Editas Medicine Cut to Underweight From Neutral by JP Morgan

Dow Jones
·
16 Dec 2024

JPMorgan Downgrades Editas Medicine to Underweight From Neutral

MT Newswires Live
·
16 Dec 2024

U.S. RESEARCH ROUNDUP-Amazon, Ford, Netflix

Reuters
·
16 Dec 2024

Analysts Offer Insights on Healthcare Companies: Affimed (AFMD), Editas Medicine (EDIT) and Trevi Therapeutics (TRVI)

TIPRANKS
·
16 Dec 2024

Editas Medicine Inc : JP Morgan Cuts to Underweight From Neutral

THOMSON REUTERS
·
16 Dec 2024

Editas Medicine: Strategic Shift and Uncertainties Prompt Hold Rating

TIPRANKS
·
14 Dec 2024

Editas Medicine price target lowered to $8 from $10 at Baird

TipRanks
·
14 Dec 2024

Brokerages downgrade gene editing company Editas to 'hold', shares slump 23%

Investing.com
·
14 Dec 2024